Walvax Biotechnology Co., Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100000WN2
CNY
13.35
0.2 (1.52%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Mar'26
Dec'25
Sep'25
Jun'25
Mar'25
Dec'24
Sep'24
Net Sales
443.85
699.43
564.60
691.95
462.26
680.10
703.60
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
443.85
699.43
564.60
691.95
462.26
680.10
703.60
Raw Material Cost
139.96
163.72
178.45
244.03
164.59
191.26
212.78
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
7.06
0.00
2.53
0.53
0.40
0.75
1.32
Selling and Distribution Expenses
112.02
458.19
292.81
339.26
237.04
490.45
261.21
Other Expenses
3.67
5.91
7.53
3.66
4.97
13.92
11.74
Total Expenditure (Excl Depreciation)
295.79
681.05
549.14
620.37
451.72
821.71
592.70
Operating Profit (PBDIT) excl Other Income
148.1
18.400000000000002
15.5
71.6
10.5
-141.6
110.9
Other Income
25.40
60.25
28.74
42.06
16.72
38.81
9.00
Operating Profit (PBDIT)
155.29
192.54
148.91
133.93
77.15
-78.72
194.25
Interest
7.06
0.00
2.53
0.53
0.40
0.75
1.32
Exceptional Items
-19.06
-62.12
78.38
-0.71
14.14
-4.65
8.32
Gross Profit (PBDT)
303.89
535.71
386.14
447.93
297.67
488.84
490.82
Depreciation
0.00
100.35
100.35
105.53
105.53
105.22
105.22
Profit Before Tax
129.18
30.06
124.41
27.16
-14.63
-189.34
96.02
Tax
14.52
8.19
13.63
14.22
4.91
-13.04
2.97
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
110.68
14.30
120.28
40.51
2.65
-114.20
85.80
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
110.68
14.30
120.28
40.51
2.65
-114.20
85.80
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
3.74
7.35
-9.68
-27.93
-22.33
-62.04
7.33
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
114.41
21.64
110.61
12.59
-19.68
-176.24
93.12
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
1.0
1.0
1.0
1.0
1.0
1.0
1.0
Reserves
7,408.48
8,620.99
9,683.24
9,496.66
9,432.19
9,429.54
9,589.64
Earnings per share (EPS)
0.07
0.01
0.08
0.03
0.0
-0.07
0.05
Diluted Earnings per share
0.07
0.01
0.08
0.03
0.0
-0.07
0.05
Operating Profit Margin (Excl OI)
29.26%
4.57%
3.51%
-1.97%
-9.75%
-32.75%
11.37%
Gross Profit Margin
29.1%
18.65%
39.81%
19.18%
19.66%
-12.37%
28.6%
PAT Margin
24.94%
2.04%
21.3%
5.86%
0.57%
-16.79%
12.19%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - YoY
stock-summary

Net Sales

YoY Growth in quarter ended Mar 2026 is -4.00% vs -22.38% in Mar 2025

stock-summary

Consolidate Net Profit

YoY Growth in quarter ended Mar 2026 is 680.71% vs -151.44% in Mar 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in quarter ended Mar 2026 is 115.07% vs -70.67% in Mar 2025

stock-summary

Interest

YoY Growth in quarter ended Mar 2026 is 1,675.00% vs -88.24% in Mar 2025

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in quarter ended Mar 2026 has improved from Mar 2025

Compare Quarterly Results Of Walvax Biotechnology Co., Ltd. With
Markets Mojo
Figures in Million
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(CNY)
Change(%)
Net Sales
443.85
0
443.85
Other Operating Income
0.00
0.00
0.00
Total Operating income
443.85
0
443.85
Raw Material Cost
139.96
0
139.96
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
7.06
0
7.06
Selling and Distribution Expenses
112.02
0
112.02
Other Expenses
3.67
0.00
3.67
Total Expenditure (Excl Depreciation)
295.79
0
295.79
Operating Profit (PBDIT) excl Other Income
148.06
0.00
148.06
Other Income
25.40
0
25.40
Operating Profit (PBDIT)
155.29
0
155.29
Interest
7.06
0
7.06
Exceptional Items
-19.06
0
-19.06
Gross Profit (PBDT)
303.89
0
303.89
Depreciation
0.00
0
0.00
Profit Before Tax
129.18
0
129.18
Tax
14.52
0
14.52
Provisions and contingencies
0
0
0.00
Profit After Tax
110.68
0
110.68
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
110.68
0
110.68
Share in Profit of Associates
0
0
0.00
Minority Interest
3.74
0
3.74
Other related items
0.00
0.00
0.00
Consolidated Net Profit
114.41
0
114.41
Equity Capital
0
0
0.00
Face Value
1.00
0
0.00
Reserves
7,408.48
0
7,408.48
Earnings per share (EPS)
0.07
0
0.07
Diluted Earnings per share
0.07
0
0.07
Operating Profit Margin (Excl OI)
29.26%
0%
0.00
29.26%
Gross Profit Margin
29.10%
0%
0.00
29.10%
PAT Margin
24.94%
0%
0.00
24.94%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 44.38 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is -36.55% vs 23.88% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is -4.00% vs -22.38% in Mar 2025

Quarterly - Consolidate Net Profit
Consolidate Net Profit 11.44 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is 429.63% vs -80.47% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 680.71% vs -151.44% in Mar 2025

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 12.99 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is -1.81% vs 10.07% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 115.07% vs -70.67% in Mar 2025

Quarterly - Interest
Interest 0.71 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is 0.00% vs -100.00% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 1,675.00% vs -88.24% in Mar 2025

Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 29.26%
in Mar 2026

Figures in %
stock-summary

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 has improved from Mar 2025